Mathematics
Probability Theory
100%
Simulation Study
92%
Covariate
73%
Competing Risk Data
66%
Quantile Regression
66%
Competing Risk
66%
Survival Time
66%
Regression Parameter
52%
Survival Data
51%
Cure Rate Model
50%
Transformation Model
50%
Time Model
48%
Failure Time
48%
Objective Function
41%
Higher Dimensions
40%
Estimating Function
37%
Fast Algorithm
33%
Statistical Approach
33%
Predictive Performance
33%
Main Effect
33%
Survivor Bias
33%
Classification Rule
33%
Reduced Model
33%
Patient Data
33%
Median Survival Time
33%
Complex Model
33%
Expectation-Maximization Algorithm
33%
Ridge Regression
33%
Inverse Gaussian Distribution
33%
Random Effects Model
33%
Count Data
33%
Likelihood Function
33%
Longitudinal Data
33%
Hitting Time
33%
Systolic Blood Pressure
33%
Treatment Group
33%
Confidence Interval
33%
Ridge
33%
Joint Modeling
33%
Dimensional Time
33%
Hemorrhage
33%
intensity function λ
33%
Statistical Analysis
33%
Complete Data
33%
Interaction Term
33%
Lower and upper bounds
33%
Statistical Method
33%
Optimal Estimate
33%
Decision Rule
33%
Quantile
28%
Keyphrases
Optimal Treatment Regime
44%
Dynamic Treatment Regime
44%
Pseudo-observations
44%
Doubly Robust Methods
44%
Joint Latent Class Model
33%
Semiparametric Mixture
33%
Mixture Components
33%
Competing Risks Data
33%
Oncological Networks
33%
Maintenance Rituximab
33%
Censored Quantile Regression
33%
Semiparametric Transformation
33%
Optimal Dynamic Treatment Regime
33%
Recurrent Event Data
33%
Cure Rate Model
33%
Accelerated Lifetime Model
33%
Multivariate Recurrent Event Data
33%
Broken Adaptive Ridge Regression
33%
Inverse Gaussian Distribution
33%
Inverse Gaussian Model
33%
Traumatic Hemorrhage
33%
Transfusion Protocol
33%
Rank Regression
33%
Time-to-event Modeling
33%
Causal Effect Estimation
33%
Semiparametric Transformation Model
33%
First Hitting Time
33%
Clofarabine
33%
Frontline Therapy
33%
Weighted Least Squares Regression
33%
Event Distribution
33%
Retapamulin
33%
Doubly Censored Data
33%
Restricted Mean Lifetime
33%
Survival Bias
33%
Intensity Model
33%
CFTR Gene
33%
Progressive Hemorrhagic Injury
33%
Hemorrhagic Progression
33%
Hypertrophic Obstructive Cardiomyopathy
33%
Septal Perforator
33%
Terminal Event
33%
Pseudo-value Approach
33%
Contrastive Learning
33%
Cluster Effect
22%
Panel Count Data
22%
Event Counts
22%
Future Outcomes
22%
Biomarker Trajectories
22%
AIDS Clinical Trials
22%
